Imatinib for priority review by US FDA for GIST recurrence.

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1654, 2008-01, pp. : 23-23

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

FDA grants priority review for prasugrel

By  

Inpharma, Vol. 1, Iss. 1627, 2008-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

The US FDA has granted priority review for bortezomib [Velcade] for the treatment of patients with newly diagnosed multiple myeloma (MM).

By  

Inpharma, Vol. 1, Iss. 1624, 2008-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

SMC accepts imatinib for GIST

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 652, 2012-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Sunitinib gets the gist in imatinib-resistance

By  

Inpharma, Vol. 1, Iss. 1491, 2005-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

US FDA to review bladder cancer risks for pioglitazone

By  

Reactions Weekly, Vol. 1, Iss. 1320, 2010-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite